Pliant Therapeutics, Inc. (PLRX)
NASDAQ: PLRX · Real-Time Price · USD
1.200
0.00 (0.00%)
May 21, 2026, 11:45 AM EDT - Market open
Pliant Therapeutics Stock Forecast
Stock Price Forecast
According to 6 analysts polled by S&P Global, Pliant Therapeutics stock has a consensus rating of "Hold" and an average price target of $2.67. The average 1-year stock price forecast is 122.50% higher than the current stock price, while the lowest is $2.00 (+66.67%) and the highest is $3.00 (+150.00%).
Price Target: $2.67 (+122.50%)
Analyst Consensus: Hold
* Price targets were last updated on Mar 13, 2026.
Analyst Ratings
The average analyst rating for Pliant Therapeutics stock is "Hold". This means that analysts believe this stock is likely to perform similarly to the overall market.
Recommendation Trends
| Rating | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 | May '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 9 | 9 | 9 | 3 | 3 | 2 |
| Sell | 1 | 1 | 1 | 1 | 1 | 1 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 11 | 11 | 11 | 5 | 5 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Canaccord Genuity | Canaccord Genuity | Hold Maintains $4 → $3 | Hold | Maintains | $4 → $3 | +150.00% | Mar 13, 2026 |
| Piper Sandler | Piper Sandler | Buy Maintains $4 → $3 | Buy | Maintains | $4 → $3 | +150.00% | Mar 12, 2026 |
| RBC Capital | RBC Capital | Hold Maintains $3 → $2 | Hold | Maintains | $3 → $2 | +66.67% | Nov 7, 2025 |
| JP Morgan | JP Morgan | Hold → Sell Downgrades n/a | Hold → Sell | Downgrades | n/a | n/a | Oct 10, 2025 |
| Piper Sandler | Piper Sandler | Buy Maintains $17 → $4 | Buy | Maintains | $17 → $4 | +233.33% | Aug 8, 2025 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-1.49
from -2.43
EPS Next Year
-1.08
from -1.49
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | n/a | n/a | ||||||
| Avg | n/a | n/a | ||||||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | -1.40 | 0.48 | ||||||
| Avg | -1.49 | -1.08 | ||||||
| Low | -1.63 | -1.53 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
Sources: Price targets and consensus ratings provided by S&P Global Market Intelligence. Historical ratings and analyst data provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data sources.